奥拉帕利治疗铂敏感复发性卵巢癌按BRCA突变和同源重组缺陷状态分组:II期LIGHT研究主要分析
LIGHT研究为II期开放标签多中心研究,评估奥拉帕利对铂敏感复发性卵巢癌按胚系BRCA突变、体细胞BRCA突变、HRD阳性无BRCA突变及HRD阴性分组的疗效。主要终点客观缓解率在四组分别为69.3%、64.0%、29.4%和10.1%,BRCA突变组疗效最佳,安全性与此前研究一致。
要点
- 奥拉帕利在胚系BRCA突变、体细胞BRCA突变、HRD阳性无BRCA突变及HRD阴性组客观缓解率分别为69.3%、64.0%、29.4%、10.1%。
- 中位无进展生存期在四组分别为11.0、10.8、7.2和5.4个月。
- 最常见(≥20%)治疗中出现的不良事件包括恶心、疲乏/乏力、呕吐、贫血、便秘、腹泻和食欲下降。
核心结论
- 奥拉帕利在所有队列中均显示活性,BRCA突变队列(无论胚系或体细胞)疗效最佳,无BRCA突变者中HRD阳性队列疗效优于HRD阴性队列。
研究设计与样本
- II期开放标签多中心研究LIGHT(NCT02983799),纳入272例铂敏感复发性卵巢癌且既往至少一线含铂化疗患者,按胚系BRCA突变、体细胞BRCA突变、HRD阳性无BRCA突变、HRD阴性分组;271例接受奥拉帕利,270例纳入疗效分析。
主要发现
- 客观缓解率在胚系BRCA突变组为69.3%,体细胞BRCA突变组为64.0%,HRD阳性无BRCA突变组为29.4%,HRD阴性组为10.1%。
- 疾病控制率在胚系BRCA突变组为96.0%,体细胞BRCA突变组为100.0%,HRD阳性无BRCA突变组为79.4%,HRD阴性组为75.3%。
- 中位无进展生存期在胚系BRCA突变组为11.0个月,体细胞BRCA突变组为10.8个月,HRD阳性无BRCA突变组为7.2个月,HRD阴性组为5.4个月。
- 最常见(≥20%)治疗中出现的不良事件包括恶心、疲乏/乏力、呕吐、贫血、便秘、腹泻和食欲下降。
关键数值与推荐
- HRD阳性肿瘤定义为基因组不稳定评分≥42。
- 肿瘤分析使用Myriad BRACAnalysis CDx和myChoice HRD检测。
- 主要终点为研究者评估的客观缓解率,次要终点包括疾病控制率和无进展生存期。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Olaparib treatment resulted in significant improvement in objective response rates (ORRs) and progression-free survival (PFS) over non‑platinum chemotherapy in patients with BRCA1/BRCA2-mutated (BRCAm) platinum-sensitive relapsed ovarian cancer (PSROC) and ≥2 prior lines of platinum-based chemotherapy in the phase III SOLO3 study. LIGHT (NCT02983799) prospectively evaluated olaparib treatment for patients with PSROC and known BRCAm and homologous recombination deficiency (HRD) status. METHODS: In this phase II open-label multicenter study, patients with PSROC and ≥1 prior line of platinum-based chemotherapy were assigned to cohorts by presence of germline BRCAm (gBRCAm), somatic BRCAm (sBRCAm), HRD-positive tumors without BRCAm, or HRD-negative tumors. The primary endpoint was investigator-assessed ORR. Secondary endpoints included disease control rate (DCR) and PFS. Tumors were analyzed using Myriad BRACAnalysis CDx and myChoice HRD assays; HRD-positive tumors were defined using a genomic instability score of ≥42. RESULTS: Of 272 enrolled patients, 271 received olaparib and 270 were included in efficacy analyses. At data cut-off, ORRs in the gBRCAm, sBRCAm, HRD-positive, and HRD-negative cohorts were 69.3%, 64.0%, 29.4%, and 10.1%, respectively. DCRs were 96.0%, 100.0%, 79.4%, and 75.3% in each cohort, respectively. Median PFS was 11.0, 10.8, 7.2, and 5.4 months, respectively. The most common (≥ 20%) treatment-emergent adverse events included nausea, fatigue/asthenia, vomiting, anemia, constipation, diarrhea, and decreased appetite. CONCLUSIONS: Olaparib treatment demonstrated activity across all cohorts. The greatest efficacy was observed in the BRCAm cohorts, regardless of gBRCAm/sBRCAm. For patients without a BRCAm, greater efficacy was observed in the HRD-positive than the HRD-negative cohorts. The safety profile was consistent with that established in previous olaparib studies.
引用
- Cadoo K, Simpkins F, Mathews C, et al. Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis. Gynecol Oncol. 2022. PMID: 35803835. doi:10.1016/j.ygyno.2022.06.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。